INNOCARE ANNOUNCES PHASE II STUDY RESULTS OF TYK2 INHIBITOR SOFICITINIB MEET PRIMARY ENDPOINT IN PATIENTS WITH VITILIGO

Reuters · 2d ago

Please log in to view news